Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Soleus Capital Management, L.P.
Form 13F · Q2 2026

Soleus Capital Management, L.P.

CIK 1802630Filed 2026-08-1113F-HR View the filing on EDGAR ↗
$2.9B
Reported book value
97
Positions
12
Quarters on record
Top 50
Positions

Soleus Capital Management, L.P. — holdings

Top 50 positions of 97, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1KRYS Krystal Biotech Inc939,254−18.5%$349M12.0%
2CELC Celcuity Inc1.7M+32.7%$178M6.1%
3TGTX Tg Therapeutics Inc2.9M−27.3%$161M5.5%
4PODD Insulet Corp1.0M+86.5%$160M5.5%
5NVCR Novocure Ltd9.9M−5.5%$150M5.2%
6UTHR United Therapeutics Corp Del225,587+20.5%$122M4.2%
7INSPIRE MED SYS INC Inspire Med Sys Inc1.9M+235.1%$86M3.0%
8RIGL Rigel Pharmaceuticals Inc1.8M+18335.0%$72M2.5%
9ANIP Ani Pharmaceuticals Inc867,760+5.8%$72M2.5%
10BBNX Beta Bionics Inc4.4M+0.9%$69M2.4%
11VCEL Vericel Corp1.5M−42.8%$65M2.2%
12PRAX Praxis Precision Medicines I177,517−46.3%$59M2.0%
13GERN Geron Corp42.8M+3.1%$55M1.9%
14ALKS Alkermes Plc1.0M−47.8%$54M1.9%
15ERAS Erasca Inc2.7M—$49M1.7%
16NPCE Neuropace Inc2.9M−0.7%$46M1.6%
17PGNY Progyny Inc1.6M−22.5%$46M1.6%
18INDIVIOR PHARMACEUTICALS INC Indivior Pharmaceuticals Inc1.1M−16.5%$44M1.5%
19PBLS Parabilis Medicines Inc1.5M—$40M1.4%
20FOCL Edap Tms S A7.3M+0.0%$38M1.3%
21GMED Globus Med Inc468,922−35.7%$37M1.3%
22RCUS Arcus Biosciences Inc1.2M+158.6%$36M1.2%
23SNDX Syndax Pharmaceuticals Inc1.6M−5.7%$36M1.2%
24NRIX Nurix Therapeutics Inc1.5M+56.2%$36M1.2%
25LEGN Legend Biotech Corp1.2M—$35M1.2%
26JBIO Jade Biosciences Inc1.6M+94.6%$34M1.2%
27UNH Unitedhealth Group Inc80,000—$33M1.1%
28AVTX Avalo Therapeutics Inc1.7M+274.4%$31M1.1%
29URGN Urogen Pharma Ltd829,810+14.1%$31M1.1%
30MBX Mbx Biosciences Inc515,279+188.0%$28M1.0%
31PALI Palisade Bio Inc13.1M—$27M0.9%
32PHVS Pharvaris N V730,907+4.1%$25M0.9%
33ORGO Organogenesis Hldgs Inc10.1M+0.5%$25M0.8%
34SUPN Supernus Pharmaceuticals520,000—$24M0.8%
35PRCT Procept Biorobotics Corp1.0M+526.9%$23M0.8%
36TNGX Tango Therapeutics Inc709,000+57.6%$22M0.8%
37IKT Inhibikase Therapeutics Inc10.9M+0.0%$22M0.8%
38TRVI Trevi Therapeutics Inc1.2M−27.2%$22M0.8%
39BMRN Biomarin Pharmaceutical Inc375,572−42.3%$21M0.7%
40LIVN Livanova Plc254,957−56.2%$21M0.7%
41ARGX Argenx Se19,955+470.1%$19M0.6%
42NVCT Nuvectis Pharma Inc1.0M—$18M0.6%
43CAPR Capricor Therapeutics Inc761,737—$18M0.6%
44EWTX Edgewise Therapeutics Inc450,889−68.9%$18M0.6%
45PRLD Prelude Therapeutics Inc3.4M—$18M0.6%
46XENE Xenon Pharmaceuticals Inc267,000−8.6%$16M0.6%
47CCCC C4 Therapeutics Inc3.4M−11.2%$16M0.5%
48KINIKSA PHARMACEUTICALS INTL Kiniksa Pharmaceuticals Intl246,353−52.7%$16M0.5%
49KIDS Orthopediatrics Corp732,144+19.0%$14M0.5%
50AVALYN PHARMACEUTICALS INC Avalyn Pharmaceuticals Inc419,000—$14M0.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.